Login to Your Account

Carfilzomib NDA Next Year

Proteolix's Proteasome Inhibitor Drives Much-Awaited Onyx Deal

By Jennifer Boggs

Tuesday, October 13, 2009
Two months after a hefty capital raise signaled a prospective shopping spree for Onyx Pharmaceuticals Inc., the Emeryville, Calif.-based firm snatched up Proteolix Inc. in a potential $851 million deal centered on carfilzomib, a proteasome inhibitor poised to take on Velcade (bortezomib) in the multiple myeloma space. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription